Genetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease

Authors

Behzad Poopak Islamic Azad University, Tehran Medical Sciences Branch

Maed Heidari Islamic Azad University, Tehran Medical Sciences Branch

Nazila Safari Payvand Clinical and Specialty Laboratory

Parviz Fallah Alborz University of Medical Sciences

Saghar Rabieipoor Payvand Clinical and Specialty Laboratory

Shahram Taghdisi Department of Hematology, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran

Zahra Amiri Department of Hematology, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran

Abstract:

Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. However, impaired responses the therapy as well as resistance to the therapy have also been reported. Genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influence the antiplatelet effect of clopidogrel. The objective of this study was to evaluate the prevalence of the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19) genotypes which are involved in the activation of clopidogrel in a random Iranian population of various ethnic groups (Persian, Azari, Kurd, etc.). Molecular analysis of CYP2C19 polymorphisms may be helpful in the determination of optimal antiplatelet therapy. Materials and Methods: CYP2C19 (*1/*2/*3) variants were assessed by Polymerase Chain Reaction-Restriction Length Polymorphism (PCR–RFLP) assays in a representative sample of 154 Iranian patients with ischemic heart disease. Results: The frequencies of CYP2C19 *1 (normal genotype), *2 (heterozygote) and *3 (homozygote) were 112 (72.7%), 36 (23.4%) and 6 (3.9%), respectively. Conclusion: The United States Food and Drug Administration (FDA) recommendations are more useful to be practiced in our country compared with other countries. Physicians should identify poor metabolizers for consideration of other antiplatelet medications or alternative dosing strategies.

Upgrade to premium to download articles

Already have an account?login

similar resources

genetic polymorphisms of cyp2c19 and resistance to clopidogrel therapy among iranian patients suffering from ischemic heart disease

background: clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. however, impaired responses the therapy as well as resistance to the therapy have also been reported. genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influen...

full text

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test.Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosage...

full text

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

full text

Frequency of Clopidogrel Resistance in Patients of Ischemic Heart Disease

Ischemic heart disease is a major public health problem and a leading cause of death in the world. Its risk increases with age, smoking, hypercholesterolemia, diabetes and hypertension [1]. Currently, cardiovascular diseases accounts for 16.7 million deaths worldwide each year and strategies for improving prevention and management of thrombotic conditions are required [2]. The most commonly use...

full text

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”

full text

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients

OBJECTIVE To investigate the association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance (CR) in patients with cardiovascular disease in Beijing district. METHODS In total, 325 patients were enrolled in the study, including 101 experimental group patients and 224 control group patients. The experimental group was divided into CR group (n=30) and non-CR group (n=71) accordin...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}

Journal title

Research in Molecular Medicine

volume 4 issue 3

pages 41- 46

publication date 2016-08

unfollow

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com